Answers are grounded in this paper and cite their sources.
A case report reveals acute interstitial lung disease in a patient with metastatic sarcoma, suggesting careful monitoring is needed with pazopanib treatment.
Pazopanib is used in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. While pneumothorax is a recognized pulmonary complication, interstitial lung disease (ILD) typically occurs after months of therapy. We present a rare case of acute onset ILD occurring within 72 hours of initiating pazopanib in a 43-year-old male with metastatic sarcoma and a history of ulcerative colitis. The patient developed rapidly progressive hypoxemic respiratory failure shortly after starting pazopanib. Extensive infectious and autoimmune workups were negative. Imaging findings, combined with a favorable clinical response to corticosteroids, supported the diagnosis of drug-induced ILD (DILD). The clinical course was further complicated by a persistent right-sided pneumothorax and ultimately fatal respiratory failure. This case highlights the potential for acute pazopanib-associated ILD, particularly in patients with predisposing risk factors.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: